The implementation of the national standard for traditional Chinese medicine formula granules, related companies are concerned by institutions and investors

[Pharmaceutical Network Market Analysis] Chinese medicine formula granules are granules made from single-flavored pieces of Chinese medici.
Compared with traditional decoction pieces, it has the advantage of being directly brewed and taken, which is convenient and qui.
With the completion of the pilot work of traditional Chinese medicine formula granules, the industry has begun to implement national standards, and policies encourage formula granules to be included in medical insuran.
The market space is expected to reach 50-60 billion yu.
In the face of considerable market space, many pharmaceutical companies are currently actively deploying and continuing to carry out the filing of traditional Chinese medicine formula granules products, and there is continuous good ne.
For example, Jilin Aodong announced on May 19 that Yanbian Pharmaceutical, a holding subsidiary of the company, received 8 "Chinese Medicine Formula Granules Listing Recording Certificate.
Specifically: Goose does not eat grass formula granules, coke betel nut formula granules, Shayuanzi formula granules, Impatiens Tobone Grass formula granules, fried betel nut formula granules, mallow fruit formula granules, wine white peony formula granules, Mimeng flower formula granul.
As of the date of the announcement, the company has obtained a total of 170 "Chinese Medicine Formula Granules Listing Recording Certificate.
Recently, a large number of pharmaceutical companies have received the attention of institutions and investors, including Xintian Pharmaceutical, Liuyao, and Yibai Pharmaceutic.
Among them, on May 19, Yibai Pharmaceutical targeted the companies concerned by investors on the interactive platform, "How many varieties of traditional Chinese medicine granules have been put on the market? How many new varieties are expected to enter the market this year?" The question said that in 2021, the company will complete the The clinical trial of Pearl Dropping Pills for the treatment of recurrent oral ulcers Phase III clinical trials and the experimental results were obtained; a total of 9 drug re-registration approvals such as Ejiao Sanbao Ointment were obtained; a total of 401 Baishao Formula Granules, Banlangen Formula Granules, and Aiye Formula Granules were complet.
Clinical research work of 100 varieties of Chinese medicine and obtained pilot approval; registered and established a wholly-owned subsidiary, Guizhou Yibai Traditional Chinese Medicine Formula Granules Pharmaceutical .
, L.
, to accelerate the production of traditional Chinese medicine formula granules; The quality standards for traditional Chinese medicinal materials and ethnic medicinal materials in Guizhou Province have been revised; at present, the relevant research work on the filing of national standard varieties and provincial standard varieties of traditional Chinese medicine formula granules is being carried o.
Research work, as well as provincial standard varieties review and resear.
Liuyao .
, L.
replied to investors on May 13 that the company's traditional Chinese medicine formula granule product filing work is continuing, and some varieties have been filed and have been listed for sale in mid-Apr.

This matter has not yet had a significant impact on the company's operating performan.

For the specific situation of the company's operating performance, please pay attention to the company's subsequent periodic reports disclos.

Xintian Pharmaceutical released a record form of investor relations activities on March 3 During the interactive session, the institution paid attention to the company's national standard filing and sales arrangements for formula granul.

In this regard, the company stated that at present, the company's traditional Chinese medicine formula granules have completed the filing of 60 national standard varieties, and the original Guizhou provincial standard varieties are currently on sa.

The company will continue to advance the filing of national standard varieti.

As a new business segment of the company, traditional Chinese medicine formula granules are currently being promoted in Guizhou Province, which is still in its infan.

A small amount of sales has been achieved in 202 In 2022, the company will further increase its promotion efforts to improve the market in Guizhou Provin.

The sales volume of traditional Chinese medicine formula granules is relatively small in the three-year doubling pl.

According to a research report released by Guohai Securities recently, the implementation of the national standard and the implementation of the filing system for cross-provincial sales of formula granules will benefit the market-oriented development of the formula granule industry in the long r.

Leading companies have advantages in origin, technology, resources, scale, e.

, and they are optimistic about Hengqiang, such as China Traditional Chinese Medicine, Kangrentang, China Resources Sanjiu, Shenwei Pharmaceutical,e.

It is recommended to focus on China Traditional Chinese Medicine, Hongri Pharmaceutical, and China Resources Sanj.

Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.